Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test - moving forward towards model-development study
- None.
- None.
Insights
The advancement in assays by Immunovia signals a substantive progression in the diagnostic landscape for pancreatic cancer. The transition from the IMMray platform to the automated ELISA platform could be a game-changer in terms of scalability and cost-efficiency. By focusing on the 15 protein biomarkers identified, Immunovia is honing in on a more targeted approach that may enhance the accuracy of early-stage pancreatic cancer detection. This precision is pivotal because pancreatic cancer has notoriously been difficult to diagnose in its early stages, often leading to late-stage discovery and poorer prognoses.
From a medical research perspective, the successful development of these assays represents a potential leap forward in diagnostic capabilities. The specificity and sensitivity of these tests are key indicators of their effectiveness. The clinical performance of the test, which will be understood better after the model-development study, will be important in determining the test's viability for widespread clinical use. It's also worth noting the potential impact on healthcare costs and patient outcomes, as earlier detection typically correlates with better treatment options and survival rates.
Immunovia's strategic pivot to leverage commercial reagents and the ELISA platform could potentially disrupt the market for pancreatic cancer diagnostics. The reduction in lead-time for production and cost of goods sold may not only improve profit margins but also make the test more accessible to the market. Considering that the U.S. is the largest market for pancreatic cancer detection and with an estimated 1.8 million high-risk individuals, the financial implications for Immunovia could be significant.
Furthermore, the stock market often reacts positively to advancements that have the potential to capture large market shares or create new markets altogether. The success of these assays and the subsequent model-development study could be a catalyst for investor interest, particularly if the clinical performance data aligns with the current positive narrative. However, it's important to monitor how Immunovia manages its go-to-market strategy and navigates the regulatory environment, which will be critical in determining the long-term success of the product and the company.
Immunovia's announcement is likely to be scrutinized by investors for its potential impact on the company's financial health. The shift to a more cost-effective production method could improve Immunovia's gross margins, which is a key metric for profitability. Additionally, the company's ability to expedite the development process using the ELISA platform may lead to a faster time-to-market, providing a competitive advantage and possibly a first-mover benefit in certain market segments.
Investors should consider the R&D costs associated with the development of these assays and the model-development study, as well as the potential revenue from the commercialization of the test. It's also prudent to evaluate the company's cash flow and capital requirements to sustain operations until the product reaches the market. The anticipation of the study results in Q2 2024 could influence stock volatility in the short term. Long-term value, however, will largely depend on the test's clinical efficacy, market adoption and the company's ability to navigate the competitive landscape of medical diagnostics.
As announced in November 2023, Immunovia successfully finalized a discovery study that evaluated nearly 3,000 proteins to identify 15 promising protein biomarkers for its next-generation test to detect early-stage pancreatic cancer.
As the next milestone in developing its next-generation test Immunovia, in collaboration with the company's research and development partner Proteomedix (an Onconetix company), has developed accurate and reliable assays to measure the most promising proteins identified in the discovery study to move forward to a model-development study.
The newly developed assays leverage commercial reagents and an automated, high-throughput ELISA testing platform. By moving from the proprietary IMMray platform used for Immunovia's prior test, IMMray PanCan-d, to the widely used commercial ELISA platform, Immunovia expects to substantially reduce lead-time in production as well as cost of goods sold for its next generation test.
"Successfully developing assays to measure the promising protein biomarkers is a critical step in developing our next-generation test. The team's pace in developing the assays was tremendous. Leveraging the ELISA platform enabled us to move quickly and will also lower our future testing costs," said Jeff Borcherding, Immunovia CEO.
Immunovia is currently conducting a model-development study for the next-generation test in which it will select the highest performing biomarkers to include in the test, define the algorithm to produce a diagnostic result, and provide an initial assessment of the test's clinical performance (i.e., sensitivity and specificity). As previously communicated, the company expects to release the results of the model development study early in Q2 2024.
For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
+46 709 11 56 08
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF) |
View original content:SOURCE Immunovia AB
FAQ
What is the purpose of Immunovia's next-generation test for pancreatic cancer?
Who is Immunovia collaborating with to develop accurate assays for the test?
What platform is Immunovia leveraging for the newly developed assays?
What milestone has Immunovia achieved in the development of its next-generation test?
When does Immunovia expect to release the results of the model development study?
